Streetbeat News

Analyst Ratings

AKRO

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Akero Therapeutics (NASDAQ:AKRO) and maintained a $40 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:25 pm

DOW

KRO

SCCO

The article discusses three materials sector stocks with over 5% dividend yields, as rated by Wall Street's most accurate analysts according to Benzinga's Analyst Stock Ratings. Kronos Worldwide, Inc. (KRO) has a dividend yield of 9.30% but reported a net loss in Q3. Dow Inc. (DOW) offers a 5.69% yield and reported a sales decline but beat consensus in Q3. Southern Copper Corporation (SCCO) has a 5.70% yield and its shares gained around 14% year-to-date.

Portfolio Pulse from Lisa Levin

November 14, 2023 | 12:22 pm

ASUR

Needham analyst Joshua Reilly has reiterated a Buy rating on Asure Software (NASDAQ:ASUR) and maintained a $20 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:22 pm

UEC

HC Wainwright & Co. analyst Heiko Ihle has reaffirmed a Buy rating on Uranium Energy Corp (AMEX:UEC) and increased the price target from $8.00 to $8.25.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:21 pm

XPER

Rosenblatt analyst Steven Frankel has reiterated a Buy rating on Xperi (NYSE:XPER) and maintained a $15 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:19 pm

AUMN

HC Wainwright & Co. analyst Heiko Ihle has maintained a Buy rating on Golden Minerals (AMEX:AUMN) but has reduced the price target from $9 to $3.1.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:18 pm

SKIN

Raymond James analyst Olivia Tong has downgraded Beauty Health (NASDAQ:SKIN) from Market Perform to Underperform, indicating a negative outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:17 pm

BWEN

HC Wainwright & Co. analyst Amit Dayal has maintained a Buy rating on Broadwind (NASDAQ:BWEN) but has reduced the price target from $12 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:14 pm

OCUP

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Ocuphire Pharma (NASDAQ:OCUP) and maintained a $20 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:13 pm

UBX

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Unity Biotechnology (NASDAQ:UBX) and maintained a price target of $10. This reaffirmation of the company's stock rating and price target suggests continued confidence in Unity Biotechnology's potential.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:11 pm